NeuroOne Medical Technologies (NeuroOne Medical Technologies) Debt-to-Equity : 0.04 (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is NeuroOne Medical Technologies Debt-to-Equity?

NeuroOne Medical Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.13 Mil. NeuroOne Medical Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.02 Mil. NeuroOne Medical Technologies's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $4.42 Mil. NeuroOne Medical Technologies's debt to equity for the quarter that ended in Dec. 2023 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for NeuroOne Medical Technologies's Debt-to-Equity or its related term are showing as below:

NMTC' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.8 Med: 0.02 Max: 0.64
Current: 0.04

During the past 13 years, the highest Debt-to-Equity Ratio of NeuroOne Medical Technologies was 0.64. The lowest was -1.80. And the median was 0.02.

NMTC's Debt-to-Equity is ranked better than
83.64% of 709 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs NMTC: 0.04

NeuroOne Medical Technologies Debt-to-Equity Historical Data

The historical data trend for NeuroOne Medical Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroOne Medical Technologies Debt-to-Equity Chart

NeuroOne Medical Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Debt-to-Equity

Get a 7-Day Free Trial

0.64

0.05

0.02

0.03

NeuroOne Medical Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.03	0.04	0.06	0.03	0.04

Competitive Comparison of NeuroOne Medical Technologies's Debt-to-Equity

For the Medical Devices subindustry, NeuroOne Medical Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroOne Medical Technologies's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where NeuroOne Medical Technologies's Debt-to-Equity falls into.

NeuroOne Medical Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

NeuroOne Medical Technologies's Debt to Equity Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.129	+	0.055)	/	6.249
	=	0.03

NeuroOne Medical Technologies's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.133	+	0.021)	/	4.418
	=	0.03

NeuroOne Medical Technologies (NAS:NMTC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

NeuroOne Medical Technologies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of NeuroOne Medical Technologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroOne Medical Technologies (NeuroOne Medical Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroOne Medical Technologies Corp (NAS:NMTC) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

7599 Anagram Dr., Eden Prairie, MN, USA, 55344

Website

https://www.n1mtc.com

NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.

Executives

Mark Christianson	10 percent owner, officer: VP, Business Dev and Marketing	10006 LIATRIS LANE, EDEN PRAIRIE MN 55347
Ronald W. Mcclurg	officer: Chief Financial Officer	C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
David A Rosa	director, officer: CEO and President	10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Hijaz Haris	officer: VP of Marketing	C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
Morgan C. Frank	10 percent owner	2 CALLE NAIRN, UNIT 701, SAN JUAN PR 00907
Manchester Management Co Llc	10 percent owner	3 WEST HILL PLACE, BOSTON MA 02110
Manchester Explorer, L.p.	10 percent owner	MANCHESTER MANAGEMENT COMPANY, L.L.C, 3 WEST HILL PLACE, Boston ma 02114
James E Besser	10 percent owner	3 WEST HILL PLACE, BOSTON MA 02114
Manchester Management Pr, Llc	10 percent owner	3 WEST HILL PLACE, BOSTON MA 02114
Edward Andrle	director	C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DRIVE, EDEN PRAIRIE MN 55344
Wade Fredrickson	10 percent owner	10006 LIATRIS LANE, EDEN PRAIRIE MN 55347
Steve Mertens	officer: Chief Technology Officer	10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343
Scott Heuler	officer: Vice President of Sales	10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343
Paul Buckman	director	12988 VALLEY VIEW RD, EDEN PRAIRIE MN 55402
Suraj Kalia	director	10006 LIATRIS LANE, EDEN PRAIRIE MN 55347